Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:13 PM
Ignite Modification Date:
2025-12-24 @ 11:13 PM
NCT ID:
NCT01482169
Eligibility Criteria:
Inclusion Criteria:
* Patients undergoing elective left heart catheterization
* Age ≥ 18 years (female not of child bearing potential)
* Able to provide written informed consent
Exclusion Criteria:
* Contraindications to administration of either Adenoscan® or Regadenoson
* High degree AV block, sick sinus syndrome without a functioning pacemaker
* Symptomatic bradycardia
* Recent STEMI (\< 5 days)
* Recent NSTEMI (\<5 days) if the peak CK is \> 1000 IU
* Dipyridamole use within 24 hours
* Adenoscan® is contraindicated (hypersensitivity to Adenoscan®, Regadenoson, or aminophylline
* Known severe bronchoconstrictive lung disease
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01482169
Study Brief:
Protocol Section:
NCT01482169